Menu
Cart 0
Make A Donation - $1,000

Make A Donation - $1,000

  • $1,000.00

All in For LLS is a fundraising campaign organized by Jared Kneitel, a 2017 candidate for Man of the Year of the Leukemia and Lymphoma Society's New York City chapter.

The Man and Woman of the Year is a prestigious ten-week fundraising competition. The male and female candidate that raises the most money for the Leukemia and Lymphoma Society between March 23 and June 1 become the Man and Woman of the Year.

The All In For LLS team is centering its campaign on raising money to research whole-exome DNA sequencing technology. This new technology just might be the key to it all.

Whole-exome sequencing literally takes a detailed look at a patient's DNA, and the DNA of cancerous cells, to custom tailor a cancer treatment to the individual patient's DNA.

This is a whole lot more specific to the patient, less invasive, and with startling ramifications for not only blood cancers, but all types of cancer.

A group of researchers is working feverishly on this new type of treatment with specific focus on pediatric acute lymphoblastic leukemia (ALL). Of course, there is loads more work to do in this area. We need to raise significant awareness for this research and funds to continue to make it happen. 1-in-10 patients diagnosed with ALL will die. Many others diagnosed with other forms of blood cancers will die.

Someday, someone can do something about that.

Today is that day and we are that someone.

Thank you for your support.
All in For LLS is a fundraising campaign organized by Jared Kneitel, a 2017 candidate for Man of the Year of the Leukemia and Lymphoma Society's New York City chapter.

The Man and Woman of the Year is a prestigious ten-week fundraising competition. The male and female candidate that raises the most money for the Leukemia and Lymphoma Society between March 23 and June 1 become the Man and Woman of the Year.

The All In For LLS team is centering its campaign on raising money to research whole-exome DNA sequencing technology. This new technology just might be the key to it all.

Whole-exome sequencing literally takes a detailed look at a patient's DNA, and the DNA of cancerous cells, to custom tailor a cancer treatment to the individual patient's DNA.

This is a whole lot more specific to the patient, less invasive, and with startling ramifications for not only blood cancers, but all types of cancer.

A group of researchers is working feverishly on this new type of treatment with specific focus on pediatric acute lymphoblastic leukemia (ALL). Of course, there is loads more work to do in this area. We need to raise significant awareness for this research and funds to continue to make it happen. 1-in-10 patients diagnosed with ALL will die. Many others diagnosed with other forms of blood cancers will die.

Someday, someone can do something about that.

Today is that day and we are that someone.

Thank you for your support.

We Also Recommend